



www.cibiltech.com

#PREDICTIVEMEDICINE
#KIDNEYTRANSPLANTATION
#CLINICALTRIALS

VALUE FOR CLIENT

Disposing of a digital predicting marker to better evaluate kidney graft survival during investigational immunosuppressants in clinical trials.

BUSINESS CASE

Providing a novel digital surrogate end point for clinical trials to foster the development of more effective immunosuppressive drugs.

VALUE FOR USER

Designing new immunosuppressants with improved long-term outcomes and better assess patients individual kidney graft loss trajectories.

INSIGHTS

Developing drugs with a design study covering 10-year graft survival is too costly and new predictive tools must emerge to accelerate clinical trials.

HELP RESEARCHERS TO SELECT NEW PROMISING IMMUNOSUPPRESSIVE DRUGS ACCORDING TO THEIR LONG-TERM OUTCOMES

Renal transplantation currently lacks robust models to predict long-term allograft failure preventing the development of effective immunosuppressive agents with greater efficacy and reduced toxicity. Next-generation clinical trials urgently need long-term outcomes which can be provided using reliable predictive tools as a realistic and feasible end point. Predigrant uses functional, immunological and histological parameters to accurately predict kidney allograft survival, leading the way to an accurate emerging surrogate end point for superiority clinical trials design. This integrative prognostic scoring digital marker will further drive the early selection of promising new drugs targets by acting as a clinical decision support system therefore facilitating faster drug development.

DATE OF CREATION

2019

GEOGRAPHIC COVERAGE

US, France, Germany

HQ LOCALIZATION

Paris, France

FOUNDERS

Stephane Tholander
Prof. Alexandre Loupy
Prof. Xavier Jouven

FUNDINGS

1M€

INVESTORS

CareDx